Cure My Disease

Don't miss your cure!

 Log in / Sign up

A radioactive 'Iron Magnet' could reveal hidden lung fungus

NCT ID NCT06244979

Diagnosis Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests whether a new imaging tracer, gallium-68-deferoxamine, can make Aspergillus fungus infections in the lungs visible on a PET/CT scan. The study involves 10 adults with suspected chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis. The goal is to see if this non-invasive scan can accurately show the infection, potentially offering an alternative to invasive procedures like bronchoscopy or lung biopsy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gallium-68-deferoxamine ([68Ga]Ga-DFO-B), a radioactive tracer for PET/CT imaging
What this could lead to
If successful, this could provide a non-invasive way to diagnose pulmonary aspergillosis, reducing the need for bronchoscopy and tissue biopsies, and potentially distinguishing infection from cancer.
What could go wrong
This is a small early-phase feasibility study with only 10 participants, so results may not generalize. The tracer's accuracy and safety need further validation, and it may not clearly differentiate infection from other conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Started

May 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient is at least 18 years old on the day of inclusion. 2. The patient has suspected chronic pulmonary aspergillosis or ABPA. 3. There is no significant interference with standard care and follow-up. Exclusion Criteria: 1. The patient is pregnant or planning on becoming pregnant. 2. The patient has severe kidney dysfunction with eGFR \< 30 ml/min/kg and/or receives dialysis. 3. The patient has (chronic) iron overload. 4. The patient has been receiving antifungal treatment for more than 48 hours prior to the study day. 5. The patient is not able to lie still in the scanner.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic bronchopulmonary aspergillosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic bronchopulmonary aspergillosis aspergillosis pulmonary aspergilloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic bronchopulmonary aspergillosis Chronic pulmonary aspergillosis Pulmonary aspergillosis

Contacts and locations

Locations

  • RadboudUMC

    Nijmegen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.